VIAF

Virtual International Authority File

Search

Leader     00000nz a2200037n 45 0
001     WKP|Q51751601  (VIAF cluster)  (Authority/Source Record)
003     WKP
005     20241121000031.0
008     241121nneanz||abbn n and d
035 ‎‡a  (WKP)Q51751601‏
024 ‎‡a  0000-0002-2720-3655‏ ‎‡2  orcid‏
035 ‎‡a  (OCoLC)Q51751601‏
100 0 ‎‡a  Frédéric Clement‏ ‎‡9  sl‏
375 ‎‡a  1‏ ‎‡2  iso5218‏
400 0 ‎‡a  Frédéric Clement‏ ‎‡c  researcher‏ ‎‡9  en‏
400 0 ‎‡a  Frédéric Clement‏ ‎‡c  wetenschapper‏ ‎‡9  nl‏
400 0 ‎‡a  Frédéric Clement‏ ‎‡c  investigador‏ ‎‡9  es‏
400 0 ‎‡a  Frédéric Clement‏ ‎‡c  investigador‏ ‎‡9  ast‏
670 ‎‡a  Author's A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration‏
670 ‎‡a  Author's A monoclonal antibody-based immunoassay to measure the antibody response against the repeat region of the circumsporozoite protein of Plasmodium falciparum‏
670 ‎‡a  Author's Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials.‏
670 ‎‡a  Author's Evaluation of a new rapid test for the combined detection of hepatitis B virus surface antigen and hepatitis B virus e antigen.‏
670 ‎‡a  Author's Evaluation of cellular immunity to mumps in vaccinated individuals with or without circulating antibodies up to 16 years after their last vaccination.‏
670 ‎‡a  Author's Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines: randomized, double-blind study in malaria-naïve adults‏
670 ‎‡a  Author's Genetic Adaptation and Neandertal Admixture Shaped the Immune System of Human Populations‏
670 ‎‡a  Author's H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses.‏
670 ‎‡a  Author's Immunogenicity and safety of a booster dose of an investigational adjuvanted polyprotein HIV-1 vaccine in healthy adults and effect of administration of chloroquine‏
670 ‎‡a  Author's Improved CD4⁺ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial.‏
670 ‎‡a  Author's Polyfunctional CD4‏
670 ‎‡a  Author's Polyfunctional CD4(+) T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine.‏
670 ‎‡a  Author's Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes‏
670 ‎‡a  Author's Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems.‏
670 ‎‡a  Author's Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 (®) adjuvant: results from a dose-finding clinical trial in older adults‏
670 ‎‡a  Author's The duration of in vitro stimulation with recall antigens determines the subset distribution of interferon-gamma-producing lymphoid cells: a kinetic analysis using the Interferon-gamma Secretion Assay.‏
670 ‎‡a  Author's Validation of an enzyme-linked immunosorbent assay for the quantification of human IgG directed against the repeat region of the circumsporozoite protein of the parasite Plasmodium falciparum‏
909 ‎‡a  (orcid) 0000000227203655‏ ‎‡9  1‏
919 ‎‡a  validationofanenzymelinkedimmunosorbentassayforthequantificationofhumaniggdirectedagainsttherepeatregionofthecircumsporozoiteproteinoftheparasiteplasmodiumfalciparum‏ ‎‡A  Validation of an enzyme-linked immunosorbent assay for the quantification of human IgG directed against the repeat region of the circumsporozoite protein of the parasite Plasmodium falciparum‏ ‎‡9  1‏
919 ‎‡a  superiorimmunogenicityofseasonalinfluenzavaccinescontainingfulldoseofmf59adjuvantresultsfromadosefindingclinicaltrialinolderadults‏ ‎‡A  Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 (®) adjuvant: results from a dose-finding clinical trial in older adults‏ ‎‡9  1‏
919 ‎‡a  strongandpersistentcd4+tcellresponseinhealthyadultsimmunizedwithacandidatehiv1vaccinecontaininggp120nefandtatantigensformulatedin3adjuvantsystems‏ ‎‡A  Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems.‏ ‎‡9  1‏
919 ‎‡a  randomizedphase1safetyimmunogenicityandmucosalantiviralactivityinyounghealthywomenvaccinatedwithhiv1gp41p1peptideonvirosomes‏ ‎‡A  Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes‏ ‎‡9  1‏
919 ‎‡a  polyfunctionalcd4‏ ‎‡A  Polyfunctional CD4‏ ‎‡9  1‏
919 ‎‡a  improvedcd4+tcellresponsestomycobacteriumtuberculosisinppdnegativeadultsbym72as01ascomparedtothem72as02andmtb72fas02tuberculosiscandidatevaccineformulationsarandomizedtrial‏ ‎‡A  Improved CD4⁺ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial.‏ ‎‡9  1‏
919 ‎‡a  immunogenicityandsafetyofaboosterdoseofaninvestigationaladjuvantedpolyproteinhiv1vaccineinhealthyadultsandeffectofadministrationofchloroquine‏ ‎‡A  Immunogenicity and safety of a booster dose of an investigational adjuvanted polyprotein HIV-1 vaccine in healthy adults and effect of administration of chloroquine‏ ‎‡9  1‏
919 ‎‡a  h5n1influenzavaccineformulatedwithas03ainducesstrongcrossreactiveandpolyfunctionalcd4tcellresponses‏ ‎‡A  H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses.‏ ‎‡9  1‏
919 ‎‡a  geneticadaptationandneandertaladmixtureshapedtheimmunesystemofhumanpopulations‏ ‎‡A  Genetic Adaptation and Neandertal Admixture Shaped the Immune System of Human Populations‏ ‎‡9  1‏
919 ‎‡a  evaluationoftheimmuneresponsetortssas01andrtssas02adjuvantedvaccinesrandomizeddoubleblindstudyinmalarianaiveadults‏ ‎‡A  Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines: randomized, double-blind study in malaria-naïve adults‏ ‎‡9  1‏
919 ‎‡a  polyfunctionalcd4+tcellresponsesinhiv1infectedviralcontrollerscomparedwiththoseinhealthyrecipientsofanadjuvantedpolyproteinhiv1vaccine‏ ‎‡A  Polyfunctional CD4(+) T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine.‏ ‎‡9  1‏
919 ‎‡a  evaluationofcellularimmunitytomumpsinvaccinatedindividualswithorwithoutcirculatingantibodiesupto16yearsaftertheirlastvaccination‏ ‎‡A  Evaluation of cellular immunity to mumps in vaccinated individuals with or without circulating antibodies up to 16 years after their last vaccination.‏ ‎‡9  1‏
919 ‎‡a  evaluationofanewrapidtestforthecombineddetectionofhepatitisbvirussurfaceantigenandhepatitisbviruseantigen‏ ‎‡A  Evaluation of a new rapid test for the combined detection of hepatitis B virus surface antigen and hepatitis B virus e antigen.‏ ‎‡9  1‏
919 ‎‡a  effectoncellularandhumoralimmuneresponsesoftheas03adjuvantsysteminanah1n12009influenzavirusvaccineadministeredtoadultsduring2randomizedcontrolledtrials‏ ‎‡A  Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials.‏ ‎‡9  1‏
919 ‎‡a  durationofinvitrostimulationwithrecallantigensdeterminesthesubsetdistributionofinterferongammaproducinglymphoidcellsakineticanalysisusingtheinterferongammasecretionassay‏ ‎‡A  The duration of in vitro stimulation with recall antigens determines the subset distribution of interferon-gamma-producing lymphoid cells: a kinetic analysis using the Interferon-gamma Secretion Assay.‏ ‎‡9  1‏
919 ‎‡a  monoclonalantibodybasedimmunoassaytomeasuretheantibodyresponseagainsttherepeatregionofthecircumsporozoiteproteinofplasmodiumfalciparum‏ ‎‡A  A monoclonal antibody-based immunoassay to measure the antibody response against the repeat region of the circumsporozoite protein of Plasmodium falciparum‏ ‎‡9  1‏
919 ‎‡a  doserangingstudyinolderadultstocomparethesafetyandimmunogenicityprofilesofmf59adjuvantedandnonadjuvantedseasonalinfluenzavaccinesfollowingintradermalandintramuscularadministration‏ ‎‡A  A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration‏ ‎‡9  1‏
946 ‎‡a  b‏ ‎‡9  1‏
996 ‎‡2  DNB|1061493652‏
996 ‎‡2  ISNI|0000000081843894‏
996 ‎‡2  ISNI|000000041034662X‏
996 ‎‡2  SUDOC|262803259‏
996 ‎‡2  SUDOC|252787420‏
996 ‎‡2  BNF|16503095‏
996 ‎‡2  ISNI|0000000504102095‏
996 ‎‡2  SUDOC|066640563‏
996 ‎‡2  NTA|429342403‏
996 ‎‡2  NDL|00666305‏
996 ‎‡2  ISNI|0000000121461808‏
996 ‎‡2  PLWABN|9810625364305606‏
996 ‎‡2  B2Q|0000014978‏
996 ‎‡2  DNB|128040475‏
996 ‎‡2  B2Q|0000103841‏
996 ‎‡2  LC|n 84027933‏
996 ‎‡2  NKC|xx0307526‏
996 ‎‡2  BNF|15366678‏
996 ‎‡2  RERO|A003112565‏
996 ‎‡2  PLWABN|9810554940105606‏
996 ‎‡2  SUDOC|232814910‏
996 ‎‡2  SUDOC|085262129‏
996 ‎‡2  NKC|osa2009541932‏
996 ‎‡2  KRNLK|KAC200609714‏
996 ‎‡2  BNF|11897022‏
996 ‎‡2  NUKAT|n 2019148397‏
996 ‎‡2  SUDOC|153842040‏
996 ‎‡2  SUDOC|092125379‏
996 ‎‡2  SUDOC|026791226‏
996 ‎‡2  BNF|14063001‏
996 ‎‡2  LC|no2006114948‏
996 ‎‡2  LC|n 96803420‏
996 ‎‡2  LC|n 87914586‏
996 ‎‡2  BNF|17782067‏
996 ‎‡2  CAOONL|ncf10819715‏
996 ‎‡2  CAOONL|ncf10819714‏
996 ‎‡2  CAOONL|ncf10819710‏
996 ‎‡2  SUDOC|170432629‏
996 ‎‡2  ISNI|0000000451265009‏
996 ‎‡2  JPG|500097034‏
996 ‎‡2  SUDOC|174929420‏
996 ‎‡2  ISNI|0000000396676912‏
996 ‎‡2  DNB|1067961615‏
996 ‎‡2  SUDOC|254124933‏
996 ‎‡2  RERO|A005510790‏
996 ‎‡2  ISNI|0000000073277247‏
996 ‎‡2  NTA|322123747‏
996 ‎‡2  ISNI|0000000451400100‏
996 ‎‡2  BIBSYS|15029917‏
996 ‎‡2  BNF|14615186‏
996 ‎‡2  DNB|119176793‏
996 ‎‡2  SZ|1188731610‏
996 ‎‡2  LIH|LNB:CB_o__v_;=B6‏
996 ‎‡2  NTA|113994214‏
996 ‎‡2  SUDOC|111673089‏
996 ‎‡2  SUDOC|266084702‏
996 ‎‡2  DNB|1188070576‏
996 ‎‡2  RERO|A013716399‏
996 ‎‡2  ISNI|0000000084650713‏
996 ‎‡2  J9U|987007434759005171‏
996 ‎‡2  SUDOC|176917837‏
996 ‎‡2  B2Q|0000685122‏
996 ‎‡2  SUDOC|086076663‏
996 ‎‡2  SZ|119176793‏
996 ‎‡2  SUDOC|191001325‏
996 ‎‡2  ISNI|0000000436421974‏
996 ‎‡2  LC|n 2013036062‏
996 ‎‡2  ISNI|0000000119270420‏
996 ‎‡2  ICCU|RAVV060870‏
996 ‎‡2  DNB|1188731610‏
996 ‎‡2  RERO|A012341427‏
996 ‎‡2  DNB|1138239801‏
996 ‎‡2  ISNI|0000000410037931‏
996 ‎‡2  ISNI|0000000432613450‏
996 ‎‡2  B2Q|0000014979‏
996 ‎‡2  NII|DA10942733‏
996 ‎‡2  SUDOC|079285805‏
996 ‎‡2  CAOONL|ncf10058578‏
996 ‎‡2  RERO|A024120581‏
996 ‎‡2  NTA|068922744‏
996 ‎‡2  NII|DA03258560‏
996 ‎‡2  RERO|A008768106‏
996 ‎‡2  LC|n 78045184‏
996 ‎‡2  BNE|XX1130645‏
996 ‎‡2  NUKAT|n 2012077717‏
996 ‎‡2  CAOONL|ncf11857843‏
997 ‎‡a  0 0 lived 0 0‏ ‎‡9  1‏